Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
Rhea-AI Summary
Lexaria (NASDAQ:LEXX) highlights rapid growth in the oral GLP-1 pill market and potential demand for its DehydraTECH delivery platform. Key industry signals include 600,000 Wegovy pill prescriptions in the first two months and analyst GLP-1 forecasts ranging up to $180B by mid-2030s. Lexaria reports DehydraTECH performance with semaglutide, tirzepatide, and liraglutide and plans 2026 R&D to explore retatrutide and amycretin applicability while engaging pharmaceutical partners.
Positive
- 600,000 Wegovy pill prescriptions in first two months
- Wegovy semaglutide franchise forecast to reach $15.9B peak revenue in 2030
- Analyst GLP-1 forecasts raised to as high as $180B
- DehydraTECH demonstrated with semaglutide, tirzepatide, liraglutide
- Planned 2026 R&D to test DehydraTECH on retatrutide and amycretin
- Active discussions underway with pharmaceutical companies about oral GLP-1 use
Negative
- Analyst GLP-1 forecasts vary widely ($101B–$180B), signaling market and revenue uncertainty
News Market Reaction – LEXX
In the Apr 21 session, LEXX declined 4.50%, reflecting a moderate negative market reaction. Argus tracked a peak move of +3.7% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 15 | Animal GLP-1 study | Positive | +1.0% | New fully funded 2026 animal study to expand DehydraTECH GLP‑1 IP. |
| Apr 07 | Peer drug approval | Positive | -6.6% | FDA approval of Eli Lilly’s oral GLP‑1 drug and supportive GLP‑1 data. |
| Apr 01 | Human GLP-1 trial | Positive | +11.0% | New 5‑week human pilot study of DehydraTECH‑semaglutide vs Wegovy tablets. |
| Mar 26 | Patent expansion | Positive | -3.1% | Five new patents in Japan and Australia for hypertension, epilepsy, diabetes. |
| Mar 24 | GLP-1 strategy update | Positive | +7.1% | Outlined oral GLP‑1 capsule/tablet strategy and large potential market size. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent GLP-1 and IP-related announcements have produced mixed reactions: three positive moves and two sell-offs on broadly positive news.
Over the last month, Lexaria reported multiple GLP-1–focused milestones and IP expansions. On Mar 24, it highlighted its oral GLP‑1 strategy and early commercial discussions, with shares up 7.12%. A new human GLP‑1 study announced on Apr 1 saw a 11.04% rise. Subsequent news on patent growth (Mar 26) and Eli Lilly’s oral GLP‑1 approval (Apr 7) led to declines of 3.15% and 6.6%. The latest animal study update on Apr 15 was followed by a modest 0.98% gain. Today’s article continues this GLP‑1 pill market narrative.
Key Terms
glp-1 medical
semaglutide medical
tirzepatide medical
liraglutide medical
retatrutide medical
fda regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
600,000 New Wegovy® Pill Prescriptions Written in First Two Months
KELOWNA, BC / ACCESS Newswire / April 21, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update of additional recent developments in the fast-moving glucagon-like peptide-1 ("GLP-1") oral (or "pill") market.
The GLP-1 oral pill sector is growing much faster in 2026 than expected, and faster than the pre-existing GLP-1 injectable sector. The industry's first-ever GLP-1 pill for weight loss, Wegovy®, was approved by the US Food and Drug Administration ("FDA") on December 22, 2025 and launched in the US in January 2026. Prior to that, Rybelsus® was the only FDA approved GLP-1 drug available in pill form, but it was approved for diabetes control and only used secondarily (or, "off label") for weight loss.
Within less than the first two months of its launch, Novo Nordisk® had disclosed that over 600,000 prescriptions for the Wegovy® pill had been written, and will report on its first-quarter sales including the Wegovy® pill in May. Both the Wegovy® injectable and the Wegovy® pill contain the same active drug: semaglutide, with which Lexaria has conducted extensive testing to determine compatibility with Lexaria's DehydraTECH™ technology.
According to Global Data Healthcare,
As Lexaria's press release of March 24 noted, TD Cowen® raised their previous 2030 sales forecast of the overall GLP-1 sector from
It is not possible to know in advance, what overall portion of the GLP-1 market will be captured by the oral pill format vs. the traditional injectable format; but, if the Wegovy® based semaglutide revenue projections are any indication, it could certainly be
This oral pill GLP-1 market is the specific market sector that Lexaria's technology is focused on. As noted within an article appearing on CNBC, "Novo Nordisk's new Wegovy® GLP-1 pill appears to be expanding the obesity treatment market, drawing in new patients rather than converting existing ones from injections." If this proves to be a sustainable trend, then a successful GLP-1 pill sector could power the broader GLP-1 market to become even larger than original projections and provide enhanced opportunities for Lexaria's DehydraTECH™.
The onset of GLP-1 drugs has radically changed the diabetes and weight-loss market sectors. The more recent onset of the GLP-1 oral pill sector is now driving revenues faster and further than injectable GLP-1 drugs alone. Lexaria's DehydraTECH™ has demonstrated performance enhancing abilities across three prominent GLP-1 drugs: semaglutide, tirzepatide and liraglutide; and Lexaria's announced 2026 Research & Development program intends to explore DehydraTECH's possible expanded applicability to next generation GLP-1 drugs including, but not limited to, retatrutide and amycretin. Lexaria remains in discussions with pharmaceutical companies related to their potential interest in DehydraTECH™ for their oral GLP-1 strategies.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on ACCESS Newswire